Health Dictionary Find a Doctor

Lyme disease

This page is about clinical aspects of the disease.  For microbiologic aspects of the causative organism(s), see Borrelia burgdorferi.

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Synonyms and keywords: Infection due to Borrelia burgdorferi sensu lato, Borreliosis, Lyme borreliosis, Steere’s disease, Afzelius syndrome, Tick-borne meningopolyneuritis, Garin-Bujadoux syndrome, Bannworth syndrome, Lymphocytic meningoradiculitis

Overview


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Lyme disease is an emerging infectious disease caused by spirochete bacteria of the genus Borrelia. The vector of infection is typically the bite of an infected black-legged or deer tick(I. scapularis), but other carriers (including other ticks in the genus Ixodes) have been implicated. Borrelia burgdorferi is the predominant cause of Lyme disease in the US and Borrelia afzelii and Borrelia garinii are the predominant causes in Europe.

The disease’s presentation varies widely, and may include rash and flu-like symptoms in its initial stage, then musculoskeletal, arthritic, neurologic, psychiatric, and cardiac manifestations. In a majority of cases, symptoms can be eliminated with antibiotics, especially if treatment begins early in the course of illness. Late or inadequate treatment often leads to “late stage” Lyme disease that is disabling and difficult to treat.

Historical Perspective

In 1883, Alfred Buchwald was the first to describe a condition associated with Lyme disease which is now known as acrodermatitis chronica atrophicans. Arvid Afzelius first observed ring-like lesions, now known as Erythema migrans, and associated the rash with tick bites. In the United States, Lyme disease was not recognized until 1975, when a cluster of cases was identified in three towns in Southeastern Connecticut (including towns Lyme and Old Lyme), which gave Lyme disease its popular name. In 1981, the infectious agent (a spirochete) was isolated by Willy Burgdorfer, a researcher at the National Institutes of Health, from the midgut of Ixodes ticks. The spirochete was named Borrelia burgdorferi in honor of Willy Burgdorfer.

Classification

Lyme disease can be classified into three stages. The first stage is localized Lyme disease, the second is disseminated Lyme disease, and the third is late disseminated Lyme disease. During stage 1, the patient can develop erythema migrans rash. Ten to twenty percent of the patients who have Lyme disease can develop post treatment Lyme disease syndrome. There are various genospecies of Borrelia burgdorferi sensu lato complex that can cause Lyme disease. A novel spirochete, Borrelia mayonii, has been recently discovered to be responsible for Lyme disease.

Pathophysiology

Lyme disease is caused by Borrelia burgdorferi and is transmitted primarily by tick species Ixodes scapularis. Ticks can attach to any part of the human body but are often found in hard-to-see areas such as the groin, armpits, and scalp. In most cases, the tick must be attached for 36 to 48 hours or more before the spirochetes can be transmitted. Very few people affected with Lyme disease recall a tick bite. B. burgdorferi has two morphological forms, a spiral form and a spheroplast form. Survival strategies of B. burgdorferi include: antigenic variation, physical sequestration, intracellular invasion, and immune system supression.

Epidemiology and Demographics

Lyme disease is the most commonly reported vector-borne illness in the United States. In 2015, it was the sixth most common nationally notifiable disease. The number of people diagnosed with Lyme disease each year in the United States is around 30,000. This disease is concentrated heavily in the Northeast and upper Midwest. Lyme disease has a seasonal variation and incidence increases during the months of May to August.

Causes

Lyme disease is caused by Gram-negative spirochetal bacteria from the genus Borrelia. At least 37 Borrelia species have been described, 12 of which are Lyme related. The Borrelia species known to cause Lyme disease are collectively known as Borrelia burgdorferi sensu lato, and have been found to have greater strain diversity than previously estimated.

Until recently, it was thought that only three genospecies caused Lyme disease: B. burgdorferi sensu stricto (predominant in North America, but also in Europe), B. afzelii, and B. garinii (both predominant in Eurasia). However, newly discovered genospecies have also been found to cause disease in humans.

Differentiating Lyme from other Disease

The differential diagnosis of Lyme disease includes babesiosis, leptospirosis, mononucleosis, viral meningitis, and chronic diseases such as SLE, fibromyalgia, and chronic fatigue syndrome. Lyme disease must be differentiated from other diseases that may cause arthralgia, fever, and skin manifestations and that are associated with a history of tick exposure. Lyme disease should also be differentiated from other causes of infectious arthritis as well as acute arthritis.

Risk Factors

Because Lyme disease is a tick-borne disease, an individual is at a heightened risk of contracting it when traveling or residing within endemic regions. Risk within endemic regions is higher during the spring and summer months, with peaks in June and July. Other factors that may increase the risk of contracting Lyme disease include owning a domesticated animal such as a dog or cat, as both of these pets may be potential hosts for a blacklegged tick. In summary, individuals who spend much of their time outdoors and/or have pets that go outdoors and who live in endemic regions, are at a higher risk of contracting tick-borne diseases.

Screening

There is insufficient evidence to recommend routine screening for Lyme disease.

Natural History, Complications and Prognosis

Lyme disease may present as a red, expanding rash called erythema migrans (EM) along with flu-like symptoms such as fatigue, arthralgia, myalgias, headache, fever and/or chills, stiff neck, anorexia, and regional lymphadenopathy. Erythema migrans resolves in approximately 28 days in untreated patients. Lyme disease is effectively managed by prompt treatment.

Untreated infection may spread from the site of the bite to other parts of the body, producing a range of symptoms including neurological, cardiac, and dermatological manifestations. Many of these symptoms will resolve over a period of weeks to months, even without treatment. However, lack of treatment can result in additional complications. Lyme arthritis is the most frequently presented symptom in late disseminated Lyme disease.

Prognosis is mainly affected by a failure to treat in a timely manner as well as simultaneous infections with other tick-borne diseases. Sometimes, patients with Lyme disease have symptoms that last months to years even after treatment with antibiotics. These symptoms includes muscle and joint pains, cognitive defects, sleep disturbance, or fatigue. The condition is referred to as post treatment Lyme disease syndrome (PTLDS).

Diagnosis

Due to the difficulty in culturing Borrelia bacteria in the laboratory, diagnosis of Lyme disease is typically based on clinical exam findings and a history of exposure to endemic areas. The erythema migrans rash, which does not occur in all cases, is considered sufficient to establish a diagnosis of Lyme disease even when serologies are negative. Serological testing can be useful, but is not diagnostic.

Clinicians who diagnose strictly based on the U.S. Centers for Disease Control (CDC) Case Definition for Lyme are in error, as the CDC explicitly states that this definition is intended for surveillance purposes only, and is “not intended to be used in clinical diagnosis.”

It is important that virtually no controlled studies of late Lyme encephalopathy have been performed, and the CDC diagnostic criteria were not formulated for use on this entity. Once Lyme disease is well established in the brain, it can occur as a very disabling diffuse encephalopathy which is difficult to diagnose using standard serological or intrathecal testing. Lyme is a deep tissue infection and by the time encephalopathy is established, few, if any CSF antibodies can be detected, and PCR is unreliable. Seronegative disease can occur for the same reason that this phenomenon occurs in neurosyphilis, with incomplete antibiotic treatment voiding the serum antibody response, but not eliminating the infection.

It is in this context that advanced imaging studies like SPECT or PET can provide objective evidence of global brain dysfunction. Resolve is often made to neuropsychological testing, but a normal result does not rule out the illness, which can be very subtle and manifest as a disabling mood disorder accompanied by massive and debilitating fatigue, with few objective signs.

Diagnosis of late stage Lyme disease it is often difficult due to the multi-faceted appearance which can mimic symptoms of many other diseases. For this reason Lyme has often been called the new “great imitator.”[1] Lyme disease may be misdiagnosed as multiple sclerosis, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome (CFS), or other autoimmune and neurodegenerative diseases.

History and Symptoms

Lyme disease is divided into 3 stages and the symptoms are stage specific. Initial symptoms include bullseye rash called erythema migrans, with accompanying flu-like symptoms. Lyme disease can progress to cardiovascular, neurological, dermatological and/or musculoskeletal manifestations. Multiple erythema migrans develops as disease disseminates throughout the body. Most common neurological manifestation includes lymphocytic meningitis and cranial nerve palsies (usually facial nerve palsy). Dermatological manifestation includes borrelial lymphocytoma and acrodermatitis chronica atrophicans appearing in stage 2 and stage 3 Lyme disease respectively. Cardiac manifestation include Lyme carditis. Musculoskeletal manifestation include Lyme arthritis. There is a difference in clinical features of Lyme disease in patients living in different geographical regions depending on the genospecies of Borrelia burgdorferi sensu lato complex causing it.

Physical Examination

The physical examination of Lyme disease is necessary for diagnosis. Erythema migrans and fever are commonly seen on physical examination in early disease. Disseminated disease is characterized by multiple erythema migrans, neurological, musculoskeletal, and cardiac symptoms.[2]

Laboratory Findings

Laboratory blood tests are helpful if used correctly and performed with validated methods. Laboratory tests are not recommended for patients who do not have symptoms typical of Lyme disease. The Centers for Disease Control recommends a two-tier testing protocol for Lyme disease. Polymerase chain reaction (PCR) tests for Lyme disease have also been developed to detect the genetic material (DNA) of the Lyme disease spirochete. Currently, PCR is the only means to detect the presence of organism. Identification and testing of the individual tick after removal is generally not useful.

Electrocardiogram

There are no ECG findings associated with Lyme disease. However, an ECG may be helpful in the diagnosis of complications of Lyme disease, which include Lyme carditis. Most of the time, Lyme carditis symptoms are related to fluctuating degrees of atrioventricular block (first-degree block to complete heart block) including lightheadedness, palpitations, shortness of breath, chest pain, and syncope.

X-ray

There are no X-ray findings associated with Lyme disease. However, an X-ray may be helpful in the diagnosis of complications of chronic Lyme arthritis.

CT Scan

There are no CT scan findings associated with Lyme disease.

MRI

MRI is not helpful in diagnosis of Lyme disease. However, an MRI may be helpful in diagnosing neurologic manifestations of early and late disseminated Lyme disease. MRI scan in patients with neurological Lyme disease may demonstrate increased intensity in white matter at multiple foci on T2-weighted images, suggesting demyelination or inflammatory changes. After antibiotic therapy, spontaneous resolution of MRI white matter hyper-intensities has been observed in Lyme disease.

Ultrasound

There are no ultrasound findings associated with Lyme disease.

Other Imaging Findings

Single photon emission computed tomography is one of the major other imaging modalities of Lyme disease. In Lyme patients, cerebral hypoperfusion of frontal subcortical and cortical structures has been found.

Other Diagnostic Studies

There are no additional diagnostic findings associated with Lyme disease.

Treatment

Medical Therapy

The mainstay of therapy for Lyme disease is antimicrobial therapy. Antimicrobial therapy may include doxycycline, amoxicillin, cephalosporins, or macrolides. The choice of antimicrobial therapy depends on the stage of Lyme disease. Individuals who remove attached ticks should be monitored closely for signs and symptoms of tick-borne diseases for up to 30 days.

Surgery

Surgical intervention is not recommended for Lyme disease.

Primary Prevention

Primary prevention of Lyme disease involves tick control and reducing exposure to ticks. The tick should be removed with proper technique so as to decrease the risk of infection. A Lyme disease vaccine used in the past is no longer available.

Secondary Prevention

The secondary prevention of Lyme disease may include post exposure prophylaxis with doxycycline in select cases meeting criteria for chemoprophylaxis.

Future or Investigational Therapies

Future and investigational therapies of Lyme disease are directed towards decreasing the pro-inflammatory immune process and decreasing Th1 upregulation. Studies have also been conducted to test the role of neurohormones in neuropsychiatric complications of Lyme disease. Other therapies including hyperbaric oxygen therapy, antifungal medications and use of bee venom are also under investigation.

References

  1. Pachner AR (1989). “Neurologic manifestations of Lyme disease, the new “great imitator“. Rev. Infect. Dis. 11 Suppl 6: S1482–6. PMID 2682960.
  2. Steere, Allen C. (1989). “Lyme Disease”. New England Journal of Medicine. 321 (9): 586–596. doi:10.1056/NEJM198908313210906. ISSN 0028-4793.


Template:WikiDoc Sources

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2], Ilan Dock, B.S.

Overview

In 1883, Alfred Buchwald was the first to describe a condition associated with Lyme disease which is now known as acrodermatitis chronica atrophicans. Arvid Afzelius first observed ring-like lesions, now known as Erythema migrans, and associated the rash with tick bites. In the United States, Lyme disease was not recognized until 1975, when a cluster of cases was identified in three towns in Southeastern Connecticut (including towns Lyme and Old Lyme), which gave Lyme disease its popular name. In 1981, the infectious agent (a spirochete) was isolated by Willy Burgdorfer, a researcher at the National Institutes of Health, from the midgut of Ixodes ticks. The spirochete was named Borrelia burgdorferi in honor of Willy Burgdorfer.

Historical Perspective

Dr. Willy Burgdorfer, an American-Swiss scientist, discovered the bacterial pathogen responsible for causing Lyme disease Source – Rocky Mountain Laboratories, National Institutes of Health

References

  1. Weber, Klaus (1993). Aspects of Lyme Borreliosis. Berlin, Heidelberg: Springer Berlin Heidelberg. ISBN 978-3-642-77614-4.
  2. Forschner, Karen (2003). Everything you need to know about Lyme disease and other tick-borne disorders. Hoboken, N.J: John Wiley. ISBN 978-0471473640.
  3. Balfour A (1911). “THE INFECTIVE GRANULE IN CERTAIN PROTOZOAL INFECTIONS, AS ILLUSTRATED BY THE SPIROCHAETOSIS OF SUDANESE FOWLS”. Br Med J. 1 (2622): 752. PMC 2333723. PMID 20765548.
  4. Dworkin, Mark S.; Schwan, Tom G.; Anderson, Donald E.; Borchardt, Stephanie M. (2008). “Tick-Borne Relapsing Fever”. Infectious Disease Clinics of North America. 22 (3): 449–468. doi:10.1016/j.idc.2008.03.006. ISSN 0891-5520.
  5. 5.0 5.1 Ryberg B (1984). “Bannwarth’s syndrome (lymphocytic meningoradiculitis) in Sweden”. Yale J Biol Med. 57 (4): 499–503. PMC 2590032. PMID 6516452.
  6. Lenhoff C (1948). “Spirochetes in aetiologically obscure diseases”. Acta Dermato-Venreol. 28: 295–324.
  7. Bianchi GE (1950). “Penicillin therapy of lymphocytoma”. Dermatologica. 100 (4–6): 270–3. PMID 15421023.
  8. Hollstrom E (1951). “Successful treatment of erythema migrans Afzelius”. Acta Derm. Venereol. 31 (2): 235–43. PMID 14829185.
  9. Paschoud JM (1954). “Lymphocytoma after tick bite”. Dermatologica (in German). 108 (4–6): 435–7. PMID 13190934.
  10. Scrimenti RJ (1970). “Erythema chronicum migrans”. Archives of dermatology. 102 (1): 104–5. PMID 5497158.
  11. Steere AC (2006). “Lyme borreliosis in 2005, 30 years after initial observations in Lyme Connecticut”. Wien. Klin. Wochenschr. 118 (21–22): 625–33. doi:10.1007/s00508-006-0687-x. PMID 17160599.
  12. Sternbach G, Dibble C (1996). “Willy Burgdorfer: Lyme disease”. J Emerg Med. 14 (5): 631–4. PMID 8933327.
  13. Mast WE, Burrows WM (1976). “Erythema chronicum migrans and “Lyme arthritis“. JAMA. 236 (21): 2392. PMID 989847.
  14. Steere AC, Malawista SE, Snydman DR; et al. (1977). “Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities”. Arthritis Rheum. 20 (1): 7–17. PMID 836338.
  15. Sanford JP (1976). “Relapsing Fever—Treatment and Control”. In Johnson RC (ed). Biology of Parasitic Spirochetes. Academic Press. ISBN 9780123870506.
  16. Steere AC, Hutchinson GJ, Rahn DW; et al. (1983). “Treatment of the early manifestations of Lyme disease”. Ann. Intern. Med. 99 (1): 22–6. PMID 6407378.
  17. Burgdorfer W (1993). “How the discovery of Borrelia burgdorferi came about”. Clin Dermatol. 11 (3): 335–8. PMID 8221514.
  18. Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ (1988). “New chemotherapeutic approaches in the treatment of Lyme borreliosis”. Ann. N. Y. Acad. Sci. 539: 352–61. PMID 3056203.
  19. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ (1990). “Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis”. Lancet. 336 (8728): 1404–6. PMID 1978873.
  20. Ribeiro JM, Mather TN, Piesman J, Spielman A (1987). “Dissemination and salivary delivery of Lyme disease spirochetes in vector ticks (Acari: Ixodidae)”. J. Med. Entomol. 24 (2): 201–5. PMID 3585913.


Template:WikiDoc Sources

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Lyme disease can be classified into three stages. The first stage is localized Lyme disease, the second is disseminated Lyme disease, and the third is late disseminated Lyme disease. During stage 1, the patient can develop erythema migrans rash. Ten to twenty percent of the patients who have Lyme disease can develop post treatment Lyme disease syndrome. There are various genospecies of Borrelia burgdorferi sensu lato complex that can cause Lyme disease. A novel spirochete, Borrelia mayonii, has been recently discovered to be responsible for Lyme disease.

Classification

Classification based on clinical stage

  • Stage 1 is called early localized Lyme disease. The infection is not yet widespread throughout the body.
  • Stage 2 is called early disseminated Lyme disease. The bacteria have begun to spread throughout the body.
  • Stage 3 is called late disseminated Lyme disease. The bacteria have spread throughout the body.

Classification based on causative organism

Borrelia burgdorferi sensu lato (s.l.) complex genospecies
Pathogenic Non-Pathogenic
Commonly infect humans Rare (no human infection) Not isolated from humans yet
  • B. bavariensis
  • B. bissettii
  • B. kurtenbachii
  • B. lusitaniae
  • B. spielmanii
  • B. valaisiana
  • B. americana
  • B. andersonii
  • B. californiensis
  • B. carolinensis
  • B. japonica
  • B. tanukii
  • B. turdi
  • B. sinica
  • B. yangtze
  • However, B. mayonii has recently been discovered to be responsible for development of Lyme disease.[2]
  • The following table demonstrates key clinical and epidemiological features that distinguish B. burgdorferi from B. mayonii:
General information B. burgdorferi B. mayonii
Transmission Tick bite Tick bite
Distribution in the USA Northeast, Mid-Atlantic, and Midwest regions Midwest region
Bacteria Concentration in Blood (Spirochetemia) Lower Higher
Early Symptoms Fever, headache, rash, neck pain Fever, headache, rash, neck pain
Late Symptoms and Complications Joint pain and arthritis Joint pain and arthritis
Nausea / Vomiting? No Yes
Rash Characteristics Bullseye target lesion Diffuse rash
Diagnosis Serology or PCR Serology or PCR
Treatment Doxycycline Doxycycline

References

  1. Rudenko N, Golovchenko M, Grubhoffer L, Oliver JH (2011). “Updates on Borrelia burgdorferi sensu lato complex with respect to public health”. Ticks Tick Borne Dis. 2 (3): 123–8. doi:10.1016/j.ttbdis.2011.04.002. PMC 3167092. PMID 21890064.
  2. Pritt, Bobbi S; Mead, Paul S; Johnson, Diep K Hoang; Neitzel, David F; Respicio-Kingry, Laurel B; Davis, Jeffrey P; Schiffman, Elizabeth; Sloan, Lynne M; Schriefer, Martin E; Replogle, Adam J; Paskewitz, Susan M; Ray, Julie A; Bjork, Jenna; Steward, Christopher R; Deedon, Alecia; Lee, Xia; Kingry, Luke C; Miller, Tracy K; Feist, Michelle A; Theel, Elitza S; Patel, Robin; Irish, Cole L; Petersen, Jeannine M (2016). “Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study” (PDF). The Lancet Infectious Diseases. 16 (5): 556–564. doi:10.1016/S1473-3099(15)00464-8. ISSN 1473-3099.


Template:WikiDoc Sources

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Lyme disease is caused by Borrelia burgdorferi and is transmitted primarily by tick species Ixodes scapularis. Ticks can attach to any part of the human body but are often found in hard-to-see areas such as the groin, armpits, and scalp. In most cases, the tick must be attached for 36 to 48 hours or more before the spirochetes can be transmitted. Very few people affected with Lyme disease recall a tick bite. B. burgdorferi have two morphological forms, a spiral form and a spheroplast form. Survival strategies of B. burgdorferi include: antigenic variation, physical sequestration, intracellular invasion, and immune system supression.

Pathophysiology

Transmission

Primary Vector

I. scapularis, the primary vector of Lyme disease in Eastern North America – Source: Gross L (2006) A New View on Lyme Disease: Rodents Hold the Key to Annual Risk. PLoS Biol 4(6): e182. https://doi.org/10.1371/journal.pbio.0040182
Relative size of I. scapularis at different life stages – Source: CDC.gov

Other Potential Vectors

Other Modes of Transmission

Reservoir host

  • The primary reservoir host of B. burgdorferi is rodents. These rodents are infested by I. scapularis.
  • The white-footed mouse (Peromyscus leucopus) is the most common rodent infected by B. burgdorferi.[18]
  • Other reservoirs may include voles, chipmunks, squirrels, raccoons, skunks, birds, and reptiles such as lizards.
  • It is predicted that the density of infected nymphal stage of ticks may be lower in areas where predators of primary reservoir hosts, particularly red foxes (Vulpes vulpes), are more active. The reason for this may include:[19]
    • Direct effect: Predation of reservoir hosts.
    • Indirect effect: Decreased movement and increased refuge due to presence of active predator.

Coinfection

Pathogenesis

Mechanisms of persistence

Role of cytokines

Evidence of a distinct pro-inflammatory immune process has been observed in both acute and antibiotic refractory Lyme disease.

Role of Neurotransmitters

Pathogenesis of Post treatment Lyme disease syndrome

Microscopic pathology

  • Biopsy of erythema migrans shows:
    • Dermal and epidermal involvement in center of lesion
    • Dermal involvement at the periphery

References

  1. 1.0 1.1 1.2 1.3 Rudenko N, Golovchenko M, Grubhoffer L, Oliver JH (2011). “Updates on Borrelia burgdorferi sensu lato complex with respect to public health”. Ticks Tick Borne Dis. 2 (3): 123–8. doi:10.1016/j.ttbdis.2011.04.002. PMC 3167092. PMID 21890064.
  2. Schwartz, Ira; Fish, Durland; Daniels, Thomas J. (1997). “Prevalence of the Rickettsial Agent of Human Granulocytic Ehrlichiosis in Ticks from a Hyperendemic Focus of Lyme Disease”. New England Journal of Medicine. 337 (1): 49–50. doi:10.1056/NEJM199707033370111. ISSN 0028-4793.
  3. Falco RC, McKenna DF, Daniels TJ, Nadelman RB, Nowakowski J, Fish D; et al. (1999). “Temporal relation between Ixodes scapularis abundance and risk for Lyme disease associated with erythema migrans”. Am J Epidemiol. 149 (8): 771–6. PMID 10206627.
  4. Piesman J, Maupin GO, Campos EG, Happ CM (1991). “Duration of adult female Ixodes dammini attachment and transmission of Borrelia burgdorferi, with description of a needle aspiration isolation method”. J Infect Dis. 163 (4): 895–7. PMID 2010643.
  5. Ohnishi J, Piesman J, de Silva AM (2001). “Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks”. Proc Natl Acad Sci U S A. 98 (2): 670–5. doi:10.1073/pnas.98.2.670. PMC 14646. PMID 11209063.
  6. 6.0 6.1 Girard YA, Travinsky B, Schotthoefer A, Fedorova N, Eisen RJ, Eisen L, Barbour AG, Lane RS (2009). “Population structure of the lyme borreliosis spirochete Borrelia burgdorferi in the western black-legged tick (Ixodes pacificus) in Northern California”. Appl. Environ. Microbiol. 75 (22): 7243–52. doi:10.1128/AEM.01704-09. PMC 2786521. PMID 19783741.
  7. Sui S, Yang Y, Sun Y, Wang X, Wang G, Shan G, Wang J, Yu J (2017). “On the core bacterial flora of Ixodes persulcatus (Taiga tick)”. PLoS ONE. 12 (7): e0180150. doi:10.1371/journal.pone.0180150. PMC 5503197. PMID 28692666.
  8. Wormser G, Masters E, Nowakowski J; et al. (2005). “Prospective clinical evaluation of patients from missouri and New York with erythema migrans-like skin lesions”. Clin Infect Dis. 41 (7): 958–65. PMID 16142659.
  9. Clark K (2004). Borrelia species in host-seeking ticks and small mammals in northern Florida” (PDF). J Clin Microbiol. 42 (11): 5076–86. PMID 15528699.
  10. Ledin K, Zeidner N, Ribeiro J; et al. (2005). “Borreliacidal activity of saliva of the tick Amblyomma americanum”. Med Vet Entomol. 19 (1): 90–95. PMID 15752182.
  11. Wormser GP, Masters E, Nowakowski J, McKenna D, Holmgren D, Ma K; et al. (2005). “Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions”. Clin Infect Dis. 41 (7): 958–65. doi:10.1086/432935. PMID 16142659.
  12. Magnarelli L, Anderson J (1988). “Ticks and biting insects infected with the etiologic agent of Lyme disease, Borrelia burgdorferi (PDF). J Clin Microbiol. 26 (8): 1482–6. PMID 3170711.
  13. Luger S (1990). “Lyme disease transmitted by a biting fly”. N Engl J Med. 322 (24): 1752. PMID 2342543.
  14. Bach G (2001). “Recovery of Lyme spirochetes by PCR in semen samples of previously diagnosed Lyme disease patients.”. 14th International Scientific Conference on Lyme Disease.
  15. Schmidt B, Aberer E, Stockenhuber C; et al. (1995). “Detection of Borrelia burgdorferi DNA by polymerase chain reaction in the urine and breast milk of patients with Lyme borreliosis”. Diagn Microbiol Infect Dis. 21 (3): 121–8. PMID 7648832.
  16. Steere AC (2003-02-01). “Lyme Disease: Questions and Answers” (PDF). Massachusetts General Hospital / Harvard Medical School. Retrieved 2007-03-22.
  17. Walsh CA, Mayer EW, Baxi LV (2007). “Lyme disease in pregnancy: case report and review of the literature”. Obstetrical & gynecological survey. 62 (1): 41–50. doi:10.1097/01.ogx.0000251024.43400.9a. PMID 17176487.
  18. Anderson JF, Johnson RC, Magnarelli LA, Hyde FW (1986). “Culturing Borrelia burgdorferi from spleen and kidney tissues of wild-caught white-footed mice, Peromyscus leucopus”. Zentralbl Bakteriol Mikrobiol Hyg A. 263 (1–2): 34–9. PMID 3577490.
  19. Hofmeester, Tim R.; Jansen, Patrick A.; Wijnen, Hendrikus J.; Coipan, Elena C.; Fonville, Manoj; Prins, Herbert H. T.; Sprong, Hein; van Wieren, Sipke E. (2017). “Cascading effects of predator activity on tick-borne disease risk”. Proceedings of the Royal Society B: Biological Sciences. 284 (1859): 20170453. doi:10.1098/rspb.2017.0453. ISSN 0962-8452.
  20. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS; et al. (2006). “The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America”. Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130.
  21. Krause PJ, McKay K, Thompson CA, Sikand VK, Lentz R, Lepore T; et al. (2002). “Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease”. Clin Infect Dis. 34 (9): 1184–91. doi:10.1086/339813. PMID 11941544.
  22. Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ, Newman JH, Rahn DW; et al. (1983). “The early clinical manifestations of Lyme disease”. Ann Intern Med. 99 (1): 76–82. PMID 6859726.
  23. Wormser GP, McKenna D, Carlin J, Nadelman RB, Cavaliere LF, Holmgren D; et al. (2005). “Brief communication: hematogenous dissemination in early Lyme disease”. Ann Intern Med. 142 (9): 751–5. PMID 15867407.
  24. 24.0 24.1 Alban PS, Johnson PW, Nelson DR (2000). “Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi”. Microbiology. 146 ( Pt 1): 119–27. PMID 10658658.
  25. 25.0 25.1 Mursic VP, Wanner G, Reinhardt S; et al. (1996). “Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants”. Infection. 24 (3): 218–26. PMID 8811359.
  26. Kersten A, Poitschek C, Rauch S, Aberer E (1995). “Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi” (PDF). Antimicrob Agents Chemother. 39 (5): 1127–33. PMID 7625800.
  27. Schaller M, Neubert U (1994). “Ultrastructure of Borrelia burgdorferi after exposure to benzylpenicillin”. Infection. 22 (6): 401–6. PMID 7698837.
  28. 28.0 28.1 Nanagara R, Duray PH, Schumacher HR Jr (1996). “Ultrastructural demonstration of spirochetal antigens in synovial fluid and synovial membrane in chronic Lyme disease: possible factors contributing to persistence of organisms”. Hum Pathol. 27 (10): 1025–34. PMID 8892586.
  29. Phillips SE, Mattman LH, Hulinska D, Moayad H (1998). “A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated”. Infection. 26 (6): 364–7. PMID 9861561.
  30. Duray PH, Yin SR, Ito Y; et al. (2005). “Invasion of human tissue ex vivo by Borrelia burgdorferi”. J Infect Dis. 191 (10): 1747–54. PMID 15838803.
  31. Gruntar I, Malovrh T, Murgia R, Cinco M (2001). “Conversion of Borrelia garinii cystic forms to motile spirochetes in vivo“. APMIS. 109 (5): 383–8. PMID 11478686.
  32. Murgia R, Cinco M (2004). “Induction of cystic forms by different stress conditions in Borrelia burgdorferi”. APMIS. 112 (1): 57–62. PMID 14961976.
  33. Brorson O, Brorson SH (1999). “An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole”. APMIS. 107 (6): 566–76. PMID 10379684.
  34. Brorson O, Brorson SH (2004). “An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to tinidazole” (PDF). Int Microbiol. 7 (2): 139–42. PMID 15248163.
  35. Brorson O, Brorson SH (2002). “An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine”. Int Microbiol. 5 (1): 25–31. PMID 12102233.
  36. Bayer ME, Zhang L, Bayer MH (1996). “Borrelia burgdorferi DNA in the urine of treated patients with chronic Lyme disease symptoms. A PCR study of 97 cases”. Infection. 24 (5): 347–53. PMID 8923044.
  37. Preac-Mursic V, Weber K, Pfister HW; et al. (1989). “Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis”. Infection. 17 (6): 355–9. PMID 2613324.
  38. Oksi J, Marjamaki M, Nikoskelainen J, Viljanen MK (1999). “Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis”. Ann Med. 31 (3): 225–32. PMID 10442678.
  39. 39.0 39.1 Embers ME, Ramamoorthy R, Philipp MT (2004). “Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease”. Microbes Infect. 6 (3): 312–8. PMID 15065567.
  40. Liang FT, Yan J, Mbow ML; et al. (2004). “Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses”. Infect Immun. 72 (10): 5759–67. PMID 15385475.
  41. Gilmore RD, Howison RR, Schmit VL; et al. (2007). “Temporal expression analysis of the Borrelia burgdorferi paralogous gene family 54 genes BBA64, BBA65, and BBA66 during persistent infection in mice”. Infect. Immun. 75 (6): 2753–64. doi:10.1128/IAI.00037-07. PMID 17371862.
  42. Miklossy J, Khalili K, Gern L; et al. (2004). “Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease”. J Alzheimers Dis. 6 (6): 639–49, discussion 673-81. PMID 15665404.
  43. Grab DJ, Perides G, Dumler JS, Kim KJ, Park J, Kim YV, Nikolskaia O, Choi KS, Stins MF, Kim KS (2005). “Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier”. Infect Immun. 73 (2): 1014–22. PMID 15664945.
  44. Ma Y, Sturrock A, Weis JJ (1991). “Intracellular localization of Borrelia burgdorferi within human endothelial cells” (PDF). Infect Immun. 59 (2): 671–8. PMID 1987083.</ref [[Fibroblasts]]<ref name=”Klempner-b”>Klempner MS, Noring R, Rogers RA (1993). “Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi”. J Infect Dis. 167 (5): 1074–81. PMID 8486939.
  45. Dorward DW, Fischer ER, Brooks DM (1997). “Invasion and cytopathic killing of human lymphocytes by spirochetes causing Lyme disease”. Clin Infect Dis. 25 Suppl 1: S2–8. PMID 9233657.
  46. Montgomery RR, Nathanson MH, Malawista SE (1993). “The fate of Borrelia burgdorferi, the agent for Lyme disease, in mouse macrophages. Destruction, survival, recovery”. J Immunol. 150 (3): 909–15. PMID 8423346.
  47. Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W (1996). “Heterogeneity of Borrelia burgdorferi in the skin”. Am J Dermatopathol. 18 (6): 571–9. PMID 8989928.
  48. Girschick HJ, Huppertz HI, Russmann H, Krenn V, Karch H (1996). “Intracellular persistence of Borrelia burgdorferi in human synovial cells”. Rheumatol Int. 16 (3): 125–32. PMID 8893378.
  49. Livengood JA, Gilmore RD (2006). “Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi”. Microbes Infect. [Epub ahead of print]. PMID 17045505.
  50. Georgilis K, Peacocke M, Klempner MS (1992). “Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro“. J Infect Dis. 166 (2): 440–4. PMID 1634816.
  51. Brouqui P, Badiaga S, Raoult D (1996). “Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin” (PDF). Antimicrob Agents Chemother. 40 (6): 1552–4. PMID 8726038.
  52. Zajkowska J, Grygorczuk S, Kondrusik M, Pancewicz S, Hermanowska-Szpakowicz T (2006). “New aspects of pathogenesis of Lyme borreliosis”. Przegla̧d epidemiologiczny (in Polish). 60 Suppl 1: 167–70. PMID 16909797.
  53. Schutzer SE, Coyle PK, Reid P, Holland B (1999). “Borrelia burgdorferi-specific immune complexes in acute Lyme disease”. JAMA. 282 (20): 1942–6. PMID 10580460.
  54. Shin JJ, Glickstein LJ, Steere AC (2007). “High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis”. Arthritis Rheum. 56 (4): 1325–35. doi:10.1002/art.22441. PMID 17393419.
  55. Rasley A, Anguita J, Marriott I (2002). “Borrelia burgdorferi induces inflammatory mediator production by murine microglia”. J. Neuroimmunol. 130 (1–2): 22–31. PMID 12225885.
  56. Rasley A, Tranguch SL, Rati DM, Marriott I (2006). “Murine glia express the immunosuppressive cytokine, interleukin-10, following exposure to Borrelia burgdorferi or Neisseria meningitidis”. Glia. 53 (6): 583–92. doi:10.1002/glia.20314. PMID 16419089.
  57. Ramesh G, Philipp MT (2005). “Pathogenesis of Lyme neuroborreliosis: mitogen-activated protein kinases Erk1, Erk2, and p38 in the response of astrocytes to Borrelia burgdorferi lipoproteins”. Neurosci. Lett. 384 (1–2): 112–6. doi:10.1016/j.neulet.2005.04.069. PMID 15893422.
  58. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP (1998). “The pathophysiologic roles of interleukin-6 in human disease”. Ann. Intern. Med. 128 (2): 127–37. PMID 9441573.
  59. Wright CB, Sacco RL, Rundek TR; et al. (2006). “Interleukin-6 is associated with cognitive function: the Northern Manhattan Study”. 15 (1): 34–38. doi:10.1016/j.jstrokecerebrovasdis.2005.08.009. PMID 16501663.
  60. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP (2005). “Cytokine dysregulation, inflammation and well-being”. Neuroimmunomodulation. 12 (5): 255–69. doi:10.1159/000087104. PMID 16166805.
  61. Calcagni E, Elenkov I (2006). “Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases”. Ann. N. Y. Acad. Sci. 1069: 62–76. doi:10.1196/annals.1351.006. PMID 16855135.
  62. Gasse T, Murr C, Meyersbach P; et al. (1994). “Neopterin production and tryptophan degradation in acute Lyme neuroborreliosis versus late Lyme encephalopathy”. European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies. 32 (9): 685–9. PMID 7865624.
  63. Jarefors S, Janefjord CK, Forsberg P, Jenmalm MC, Ekerfelt C (2007). “Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals”. Clin. Exp. Immunol. 147 (1): 18–27. doi:10.1111/j.1365-2249.2006.03245.x. PMID 17177959.
  64. Ramesh G, Philipp MT (2005). “Pathogenesis of Lyme neuroborreliosis: mitogen-activated protein kinases Erk1, Erk2, and p38 in the response of astrocytes to Borrelia burgdorferi lipoproteins”. Neurosci. Lett. 384 (1–2): 112–6. doi:10.1016/j.neulet.2005.04.069. PMID 15893422.
  65. Singh SK, Girschick HJ (2006). “Toll-like receptors in Borrelia burgdorferi-induced inflammation”. Clin. Microbiol. Infect. 12 (8): 705–17. doi:10.1111/j.1469-0691.2006.01440.x. PMID 16842565.


Template:WikiDoc Sources

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2], Ilan Dock, B.S.

Overview

Lyme disease is the most commonly reported vector-borne illness in the United States. In 2015, it was the sixth most common nationally notifiable disease. The number of people diagnosed with Lyme disease each year in the United States is around 30,000. This disease is concentrated heavily in the Northeast and upper Midwest. Lyme disease has a seasonal variation and incidence increases during months of May to August.

Epidemiology and Demographics

Incidence

  • Lyme disease is the most common tick-borne disease in North America and Europe, and one of the fastest-growing infectious diseases in the United States.
  • The number of people diagnosed with Lyme disease each year in the United States is around 30,000.[1]
  • In the United States, the incidence of Lyme disease is 8.1 per 100,000 individuals as per data collected by the Center for Disease Control (CDC) in 2016.[2]
  • In the fourteen states where Lyme disease is most common, the average was 40.4 cases for every 100,000 persons in the year 2015.[1][3]
  • Although Lyme disease has now been reported in the majority of states in the U.S, about 95% of all reported cases are confined to just five geographic areas including New England, Mid-Atlantic, East-North Central, South Atlantic, and West North-Central.[3]
Reported cases of Lyme disease in the United Stated from 2001 to 2015 – Source: CDC.gov

Seasonal Variation

Confirmed Lyme disease cases by month of disease onset–United States, 2001-2015 – Source: CDC.gov

Widespread disease and endemic regions

  • The number of reported cases of the disease has been increasing, as is the number of endemic regions in North America.
  • B. burgdorferi sensu lato has been maintained in enzootic cycles in California as well as other regions throughout North America, Europe, and North Africa. Indeed, the DNA of Borrelia has been detected in lizards, indicating that they can be infected.[6]
  • In Europe, cases of B. burgdorferi sensu lato infected ticks are found predominantly in Norway, Netherlands, Germany, France, Italy, Slovenia, and Poland, but have been isolated in almost every country on the continent. Lyme disease statistics for Europe can be found at the Eurosurveillance website.
  • B. burgdorferi sensu lato infested ticks are being found more frequently in Japan, as well as in northwest China and far eastern Russia.[7][8] Borrelia has been isolated in Mongolia as well.[9]
  • In South America, tick-borne disease recognition and occurrence is rising.
  • Ticks carrying B. burgdorferi sensu lato, as well as canine and human tick-borne disease, have been reported widely in Brazil, but the subspecies of Borrelia have not yet been defined.[10] The first reported case of Lyme disease in Brazil was in 1993 in Sao Paulo.[11]
  • B. burgdorferi sensu stricto antigens in patients have been identified in Colombia and Bolivia.
  • In Northern Africa, B. burgdorferi sensu lato has been identified in Morocco, Algeria, Egypt, and Tunisia.[12][13][14]
  • In Western and sub-Saharan Africa, tick-borne relapsing fever was first identified by the British physicians Joseph Dutton and John Todd in 1905. Borrelia in the manifestation of Lyme disease in this region is presently unknown but evidence indicates that Lyme disease may occur in humans in sub-Saharan Africa. The abundance of hosts and tick vectors would favor the establishment of Lyme infection in Africa.[15] In East Africa, two cases of Lyme disease have been reported in Kenya.[16]
  • In Australia there is no definitive evidence for the existence of B. burgdorferi or for any other tick-borne spirochete that may be responsible for a local syndrome being reported as Lyme disease.[17] Cases of neuroborreliosis have been documented in Australia but are often ascribed to travel to other continents. The existence of Lyme disease in Australia is controversial.
  • Data shows that Northern hemisphere temperate regions are most endemic for Lyme disease.[18][19]
Geographical distribution of Lyme disease – Source: WIKICOMMONS


Age

  • There’s a higher incidence of infection among children and infants of less than a year to 15 years.
  • Another peak occurs in individuals between the ages of 40 to 55 years.

Gender

  • On average, there is a higher incidence among males than females.
  • However, among people aged 70 and higher, females tend to have a higher incidence of infection.
Peaks occur in males between the ages of less than one year to 15 and 40 to 55 years. Female patients are at a slightly higher risk than male patients above the age of 70. – Source: CDC.gov

Race

References

  1. 1.0 1.1 “Lyme disease data tables | Lyme Disease | CDC”.
  2. “Data and Statistics | Lyme Disease | CDC”.
  3. 3.0 3.1 “Data and Statistics | Lyme Disease | CDC”.
  4. Schwartz, Ira; Fish, Durland; Daniels, Thomas J. (1997). “Prevalence of the Rickettsial Agent of Human Granulocytic Ehrlichiosis in Ticks from a Hyperendemic Focus of Lyme Disease”. New England Journal of Medicine. 337 (1): 49–50. doi:10.1056/NEJM199707033370111. ISSN 0028-4793.
  5. Falco RC, McKenna DF, Daniels TJ, Nadelman RB, Nowakowski J, Fish D; et al. (1999). “Temporal relation between Ixodes scapularis abundance and risk for Lyme disease associated with erythema migrans”. Am J Epidemiol. 149 (8): 771–6. PMID 10206627.
  6. Swanson KI, Norris DE (2007). “Detection of Borrelia burgdorferi DNA in lizards from Southern Maryland”. Vector Borne Zoonotic Dis. 7 (1): 42–9. doi:10.1089/vbz.2006.0548. PMID 17417956.
  7. Li M, Masuzawa T, Takada N; et al. (1998). “Lyme disease Borrelia species in northeastern China resemble those isolated from far eastern Russia and Japan”. Appl. Environ. Microbiol. 64 (7): 2705–9. PMID 9647853.
  8. Masuzawa T (2004). “Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia”. Jpn. J. Infect. Dis. 57 (6): 229–35. PMID 15623946.
  9. Walder G, Lkhamsuren E, Shagdar A; et al. (2006). “Serological evidence for tick-borne encephalitis, borreliosis, and human granulocytic anaplasmosis in Mongolia”. Int. J. Med. Microbiol. 296 Suppl 40: 69–75. doi:10.1016/j.ijmm.2006.01.031. PMID 16524782.
  10. Mantovani E, Costa IP, Gauditano G, Bonoldi VL, Higuchi ML, Yoshinari NH (2007). “Description of Lyme disease-like syndrome in Brazil. Is it a new tick borne disease or Lyme disease variation?”. Braz. J. Med. Biol. Res. 40 (4): 443–56. PMID 17401487.
  11. Yoshinari NH, Oyafuso LK, Monteiro FG; et al. (1993). “Lyme disease. Report of a case observed in Brazil”. Revista do Hospital das Clínicas (in Portuguese). 48 (4): 170–4. PMID 8284588.
  12. Bouattour A, Ghorbel A, Chabchoub A, Postic D (2004). “Lyme borreliosis situation in North Africa”. Archives de l’Institut Pasteur de Tunis (in French). 81 (1–4): 13–20. PMID 16929760.
  13. Dsouli N, Younsi-Kabachii H, Postic D; et al. (2006). “Reservoir role of lizard Psammodromus algirus in transmission cycle of Borrelia burgdorferi sensu lato (Spirochaetaceae) in Tunisia”. J. Med. Entomol. 43 (4): 737–42. PMID 16892633.
  14. Helmy N (2000). “Seasonal abundance of Ornithodoros (O.) savignyi and prevalence of infection with Borrelia spirochetes in Egypt”. Journal of the Egyptian Society of Parasitology. 30 (2): 607–19. PMID 10946521.
  15. Fivaz BH, Petney TN (1989). “Lyme disease–a new disease in southern Africa?”. Journal of the South African Veterinary Association. 60 (3): 155–8. PMID 2699499.
  16. Jowi JO, Gathua SN (2005). “Lyme disease: report of two cases”. East African medical journal. 82 (5): 267–9. PMID 16119758.
  17. Piesman J, Stone BF (1991). “Vector competence of the Australian paralysis tick, Ixodes holocyclus, for the Lyme disease spirochete Borrelia burgdorferi”. Int. J. Parasitol. 21 (1): 109–11. PMID 2040556.
  18. Grubhoffer L, Golovchenko M, Vancová M, Zacharovová-Slavícková K, Rudenko N, Oliver JH (2005). “Lyme borreliosis: insights into tick-/host-borrelia relations”. Folia Parasitol. 52 (4): 279–94. PMID 16405291.
  19. Higgins R (2004). “Emerging or re-emerging bacterial zoonotic diseases: bartonellosis, leptospirosis, Lyme borreliosis, plague”. Rev. – Off. Int. Epizoot. 23 (2): 569–81. PMID 15702720.
  20. “Racial Disparities in Nationally Notifiable Diseases — United States, 2002”.


Template:WikiDoc Sources

Causes
This page is about microbiologic aspects of the organism(s).  For clinical aspects of the disease, see Lyme disease.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2], Ilan Dock, B.S. Template:Seealso Template:Seealso (a newly discovered Borrelia species that has been associated with Lyme disease)

Overview

Borrelia burgdorferi is species of bacteria of the spirochete class of the genus Borrelia. B. burgdorferi is predominant in North America, but also exists in Europe, and is the causative agent of Lyme disease. It is a zoonotic, vector-borne disease transmitted by ticks and is named after the researcher Willy Burgdorfer who first isolated the bacterium in 1982. B. burgdorferi is one of the few pathogenic bacteria that can survive without iron, having replaced all of its iron-sulphur cluster enzymes with enzymes that use manganese, thus avoiding the problem many pathogenic bacteria face in acquiring iron. B. burgdorferi infections have been linked to non-Hodgkin lymphomas.[1]

Organism

Borrelia burgdorferi the causative agent of Lyme disease (borreliosis). Magnified 400 times. – Source: Public Health Image Library
  • Borrelia are microaerophillic and slow-growing—the primary reason for the long delays when diagnosing Lyme disease—and have been found to have greater strain diversity than previously estimated.[2] The strains differ in clinical symptoms and/or presentation as well as geographic distribution.[3]


Structure and growth

B. burgdorferi is a highly specialized, motile, two-membrane, spiral-shaped spirochete ranging from about 9 to 32 micrometers in length. It is often described as gram-negative and has an outer membrane with lipopolysaccharide (LPS), though it stains only weakly in the Gram stain. B. burgdorferi is a microaerophilic organism, requiring little oxygen to survive. It lives primarily as an extracellular pathogen, although it can also hide intracellularly (see Mechanisms of persistence section).

Like other spirochetes such as T. pallidum (the agent of syphilis), B. burgdorferi has an axial filament composed of flagella which run lengthways between its cell wall and outer membrane. This structure allows the spirochete to move efficiently in corkscrew fashion through viscous media, such as connective tissue. As a result, B. burgdorferi can disseminate throughout the body within days to weeks of infection, penetrating deeply into tissue where the immune system and antibiotics may not be able to eradicate the infection.

B. burgdorferi is very slow growing, with a doubling time of 12-18 hours[6] (in contrast to pathogens such as Streptococcus and Staphylococcus, which have a doubling time of 20-30 minutes). Since most antibiotics kill bacteria only when they are dividing, this longer doubling time necessitates the use of relatively longer treatment courses for Lyme disease. Antibiotics are most effective during the growth phase, which for B. burgdorferi occurs in four-week cycles.

Outer surface proteins

The outer membrane of Borrelia burgdorferi is composed of various unique outer surface proteins (Osp) that have been characterized (OspA through OspF). They are presumed to play a role in virulence.

OspA and OspB are by far the most abundant outer surface proteins.

The OspA and OspB genes encode the major outer membrane proteins of the B. burgdorferi. The two Osp proteins show a high degree of sequence similarity, indicating a recent evolutionary event. Molecular analysis and sequence comparison of OspA and OspB with other proteins has revealed similarity to the signal peptides of prokaryotic lipoproteins.[7]Virtually all spirochetes in the midgut of an unfed nymph tick express OspA.

OspC is an antigen-detection of its presence by the host organism and can stimulate an immune response. While each individual bacterial cell contains just one copy of the gene encoding OspC, populations of B. burgdorferi have shown high levels of variation among individuals in the gene sequence for OspC.[8] OspC is likely to play a role in transmission from vector to host, since it has been observed that the protein is only expressed in the presence of mammalian blood or tissue.[9]

The functions of OspD are unknown.

OspE and OspF are structurally arranged in tandem as one transcriptional unit under the control of a common promoter.[10]

In transmission to the mammalian host, when the nymphal tick begins to feed, and the spirochetes in the midgut begin to multiply rapidly, most spirochetes cease expressing OspA on their surface. Simultaneous with the disappearance of OspA, the spirochete population in the midgut begins to express a OspC. Upregulation of OspC begins during the first day of feeding and peaks 48 hours after attachment.[11]

General Tick Life Cycle

This image displays an example of the tick lifecycle, based on stages and the months that they are most likely to occur during. – Source: https://www.nih.gov

A tick’s life cycle is composed of four stages: hatching (egg), nymph (six legged), nymph (eight legged), and an adult.

Ticks require blood meal to survive through their life cycle.

Hosts for tick blood meals include mammals, birds, reptiles, and amphibians. Ticks will most likely transfer between different hosts during the different stages of their life cycle.

Humans are most often targeted during the nymph and adult stages of the life cycle.

Life cycle is also dependent on seasonal variation.

Ticks will go from eggs to larva during the summer months, infecting bird or rodent host during the larval stage.

Larva will infect the host from the summer until the following spring, at which point they will progress into the nymph stage.

During the nymph stage, a tick will most likely seek a mammal host (including humans).

A nymph will remain with the selected host until the following fall at which point it will progress into an adult.

As an adult, a tick will feed on a mammalian host. However unlike previous stages, ticks will prefer larger mammals over rodents.

The average tick life cycle requires three years for completion.

Different species will undergo certain variations within their individual life cycles. [12]

Borrelia burgdoferi lifecycle

The life-cycle concept encompassing reservoirs and infections in multiple hosts has recently been expanded to encompass forms of the spirochete which differ from the motile corkscrew form, and these include cystic forms spheroplast-like, straighted non-coiled bacillary forms which are immotile due to flagellin mutations and granular forms coccoid in profile. The model of Plasmodium species Malaria with multiple parasitic profiles demonstrable in various host insects and mammals is a hypothesized model for a similarly complex proposed Borrelia spirochete life cycle. [13] [14]

Whereas B. burgdorferi is most associated with deer tick and the white footed mouse,[15] B. afzelii is most frequently detected in rodent-feeding vector ticks, B. garinii and B. valaisiana appear to be associated with birds. Both rodents and birds are competent reservoir hosts for Borrelia burgdorferi sensu stricto. The resistance of a genospecies of Lyme disease spirochetes to the bacteriolytic activities of the alternative immune complement pathway of various host species may determine its reservoir host association.

Ecology

Urbanization and other anthropogenic factors can be implicated in the spread of the Lyme disease into the human population. In many areas, expansion of suburban neighborhoods has led to the gradual deforestation of surrounding wooded areas and increasing “border” contact between humans and tick-dense areas. Human expansion has also resulted in a gradual reduction of the predators that normally hunt deer as well as mice, chipmunks and other small rodents — the primary reservoirs for Lyme disease. As a consequence of increased human contact with host and vector, the likelihood of transmission of Lyme to residents of endemic area has greatly increased.[16][17] Researchers are also investigating possible links between global warming and the spread of vector-borne diseases including Lyme disease.[18]

The deer tick (Ixodes scapularis, the primary vector in the northeastern U.S.) has a two-year life cycle, first progressing from larva to nymph, and then from nymph to adult. The tick feeds only once at each stage. In the fall, large acorn forests attract deer as well as mice, chipmunks and other small rodents infected with B. burgdorferi. During the following spring, the ticks lay their eggs. The rodent population then “booms.” Tick eggs hatch into larvae, which feed on the rodents; thus the larvae acquire infection from the rodents. (Note: At this stage, it is proposed that tick infestation may be controlled using acaricides (miticide).

Adult ticks may also transmit disease to humans. After feeding, female adult ticks lay their eggs on the ground, and the cycle is complete. On the west coast, Lyme disease is spread by the western black-legged tick (Ixodes pacificus), which has a different life cycle.

The risk of acquiring Lyme disease does not depend on the existence of a local deer population, as is commonly assumed. New research suggests that eliminating deer from smaller areas (less than 2.5 hectares or 6.2 acres) may in fact lead to an increase in tick density and the rise of “tick-borne disease hotspots”.[19]

Differentiating B. burgdorferi from B. mayonii

The following table demonstrates key clinical and epidemiological features that distinguish B. burgdorferi from B. mayonii:[20][21]

General information B. burgdorferi B. mayonii
Transmission Tick bite Tick bite
Distribution in the USA Northeast, Mid-Atlantic, and Midwest regions Midwest region
Bacteria Concentration in Blood (Spirochetemia) Lower Higher
Early Symptoms Fever, headache, rash, neck pain Fever, headache, rash, neck pain
Late Symptoms and Complications Joint pain and Arthritis Joint pain and Arthritis
Nausea / Vomiting? No Yes
Rash Characteristics Bull’s-eye target lesion Diffuse rash
Diagnosis Serology or PCR Serology or PCR
Treatment Doxycycline Doxycycline


References

  1. Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R (2006). “Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives”. Clinical lymphoma & myeloma. 6 (4): 289–300. PMID 16507206.
  2. Bunikis J, Garpmo U, Tsao J, Berglund J, Fish D, Barbour AG (2004). “Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe” (PDF). Microbiology. 150 (Pt 6): 1741–55. PMID 15184561.
  3. Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. ISBN 0-8385-8529-9.
  4. Felsenfeld O (1971). Borrelia: Strains, Vectors, Human and Animal Borreliosis. St. Louis: Warren H. Green, Inc.
  5. CBS News Lyme Disease. http://www.cbsnews.com/news/lyme-disease-just-got-nastier/ Accessed February 9, 2016.
  6. Kelly, R. T. (1984). Genus IV. Borrelia Swellengrebel 1907, 582AL. In Bergey’s Manual of Systematic Bacteriology, vol. 1, pp. 57–62. Edited by N. R. Krieg & J. G. Holt. Baltimore: Williams & Wilkins.
  7. Bergstrom S. , Bundoc V.G. , Barbour A.G. Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol. Microbiol. 3 479-486 1989
  8. Girschick, J. and Singh, S.E. Molecular survival strategies of the lyme disease spirochete Borrelia burgdorferi. Sep, 2004. The Lancet Infectious Diseases: Volume 4, Issue 9, September 2004, Pages 575-583.
  9. Fikrig, E. and Pal, U. Adaptation of Borrelia burgdorferi in the vector and vertebrate host. Microbes and Infection Volume 5, Issue 7, June 2003, Pages 659-666. PMID 12787742
  10. Lam TT, Nguyen TP, Montgomery RR, Kantor FS, Fikrig E, Flavell RA. Outer surface proteins E and F of Borrelia burgdorferi, the agent of Lyme disease. Infect Immun. 1994 Jan;62(1):290-8.
  11. Schwan TG, Piesman J. Temporal changes in outer surface proteins A and C of the Lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J Clin Microbiol 2000;38:382-8.
  12. Life Cycle of Ticks that Bite Humans (2015). http://www.cdc.gov/ticks/life_cycle_and_hosts.html Accessed on December 30, 2015
  13. Macdonald AB. “A life cycle for Borrelia spirochetes?” Med Hypotheses. 2006;67(4):810-8. PMID 16716532
  14. Lymeinfo.net – LDAdverseConditions
  15. Wallis RC, Brown SE, Kloter KO, Main AJ Jr. Erythema chronicum migrans and lyme arthritis: field study of ticks. Am J Epidemiol. 1978 Oct;108(4):322-7.PMID 727201
  16. LoGiudice K, Ostfeld R, Schmidt K, Keesing F (2003). “The ecology of infectious disease: effects of host diversity and community composition on Lyme disease risk”. Proc Natl Acad Sci U S A. 100 (2): 567–71. PMID 12525705.
  17. Patz J, Daszak P, Tabor G; et al. (2004). “Unhealthy landscapes: Policy recommendations on land use change and infectious disease emergence”. Environ Health Perspect. 112 (10): 1092–8. PMID 15238283.
  18. Khasnis AA, Nettleman MD (2005). “Global warming and infectious disease”. Arch. Med. Res. 36 (6): 689–96. doi:10.1016/j.arcmed.2005.03.041. PMID 16216650.
  19. Perkins SE, Cattadori IM, Tagliapietra V, Rizzoli AP, Hudson PJ (2006). “Localized deer absence leads to tick amplification”. Ecology. 87 (8): 1981–6. PMID 16937637.
  20. Pritt, Bobbi S; Mead, Paul S; Johnson, Diep K Hoang; Neitzel, David F; Respicio-Kingry, Laurel B; Davis, Jeffrey P; Schiffman, Elizabeth; Sloan, Lynne M; Schriefer, Martin E; Replogle, Adam J; Paskewitz, Susan M; Ray, Julie A; Bjork, Jenna; Steward, Christopher R; Deedon, Alecia; Lee, Xia; Kingry, Luke C; Miller, Tracy K; Feist, Michelle A; Theel, Elitza S; Patel, Robin; Irish, Cole L; Petersen, Jeannine M (2016). “Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study”. The Lancet Infectious Diseases. 16 (5): 556–564. doi:10.1016/S1473-3099(15)00464-8. ISSN 1473-3099.
  21. “New Lyme-disease-causing bacteria species discovered| CDC Online Newsroom | CDC”.
  22. 22.00 22.01 22.02 22.03 22.04 22.05 22.06 22.07 22.08 22.09 22.10 22.11 22.12 22.13 22.14 22.15 22.16 22.17 22.18 22.19 22.20 22.21 22.22 22.23 22.24 22.25 22.26 22.27 22.28 22.29 22.30 22.31 22.32 22.33 22.34 22.35 22.36 22.37 22.38 22.39 22.40 22.41 22.42 “Public Health Image Library (PHIL)”.

See Also

  • Allen Steere
  • Jorge Benach



de:Wanderröte


Template:WS

Differentiating Lyme disease from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Lyme disease must be differentiated from babesiosis, leptospirosis, mononucleosis, viral meningitis, and chronic diseases such as SLE, fibromyalgia, and chronic fatigue syndrome.Lyme disease must be differentiated from other diseases that may cause arthralgia, fever, and skin manifestations and that are associated with a history of tick exposure. Lyme disease should also be differentiated from other causes of infectious arthritis as well as acute arthritis.

Differentiating Lyme disease from other tick-borne diseases

Lyme disease must be differentiated from other diseases that may cause arthralgia, fever, and skin manifestations and that are associated with a history of tick exposure.

Disease Organism Vector Symptoms
Bacterial Infection
Borreliosis (Lyme Disease) [1] Borrelia burgdorferi sensu lato complex and B. mayonii I. scapularis, I. pacificus, I. ricinus, and I. persulcatus Erythema migrans, flu-like illness(fatigue, fever), Lyme arthritis, neuroborreliosis, and carditis.
Relapsing Fever [2] Tick-borne relapsing fever (TBRF): Borrelia duttoni, Borrelia hermsii, and Borrelia parkerii Ornithodoros species Consistently documented high fevers, flu-like illness, headaches, muscular soreness or joint pain, altered mental status, painful urination, rash, and rigors.
Louse-borne relapsing fever (LBRF) : Borrelia recurrentis Pediculus humanus
Typhus (Rickettsia)
Rocky Mountain Spotted Fever Rickettsia rickettsii Dermacentor variabilis, Dermacentor andersoni Fever, altered mental status, myalgia, rash, and headaches.
Helvetica Spotted Fever [3] Rickettsia helvetica Ixodes ricinus Rash: spotted, red dots. Respiratory symptoms (dyspnea, cough), muscle pain, and headaches.
Ehrlichiosis (Anaplasmosis) [4] Ehrlichia chaffeensis, Ehrlichia ewingii Amblyomma americanum, Ixodes scapularis Fever, headache, chills, malaise, muscle pain, nausea, confusion, conjunctivitis, or rash (60% in children and 30% in adults).
Tularemia [5] Francisella tularensis Dermacentor andersoni, Dermacentor variabilis Ulceroglandular, glandular, oculoglandular, oroglandular, pneumonic, typhoidal.
Viral Infection
Tick-borne meningoencephalitis [6] TBEV virus Ixodes scapularis, I. ricinus, I. persulcatus Early Phase: Non-specific symptoms including fever, malaise, anorexia, muscle pains, headaches, nausea, and vomiting. Second Phase: Meningitis symptoms, headache, stiff neck, encephalitis, drowsiness, sensory disturbances, and potential paralysis.
Colorado Tick Fever [7] CTF virus Dermacentor andersoni Common symptoms include fever, chills, headache, body aches, and lethargy. Other symptoms associated with the disease include sore throat, abdominal pain, vomiting, and a skin rash. A biphasic fever is a hallmark of Colorado Tick Fever and presents in nearly 50% of infected patients.
Crimean-Congo Hemorrhagic Fever CCHF virus Hyalomma marginatum, Rhipicephalus bursa Initially infected patients will likely feel a few of the following symptoms: headache, high fever, back and joint pain, stomach pain, vomiting, flushed face, red throat petechiae of the palate, and potentially changes in mood as well as sensory perception.
Protozoan Infection
Babesiosis [8] Babesia microti, Babesia divergens, Babesia equi Ixodes scapularis, I. pacificus Non-specific flu-like symptoms.

Differentiating Lyme Arthritis from other causes of Infectious Arthritis

Microorganism or other infectious disease Associated risk factors Key clinical clues
Lyme disease
  • Living in endemic area or history of recent visit to endemic area
  • Exposure to ticks
Staphylococcus aureus
Streptococcus pyogenes

Streptococcal pneumonia

  • Healthy adults with spleenic dysfunction
Groups B Streptococcal infection
  • Healthy adults with spleenic dysfunction
Neisseria gonorrhoeae
Gram-negative bacilli
Haemophilus influenzae
  • Unimmunized children[15]
Anaerobes
Mycobacterium spp.
  • Recent history of travel to endemic areas
  • Immunocompromised patients
  • Recent history of travel to endemic areas (e.g. India, South Africa, Mexico etc.)
  • Incidious onset of monoarthritis
Fungal infection such as
Mycoplasma hominis
  • Recent history of urinary tract procedure
Viral arthritis
HIV infection
  • History of multiple sexual partners
  • History of IVDA
Reactive arthritis
  • Recent gastrointestinal/ genitourinary infection
Endocarditis

Differentiating Lyme arthritis from other causes of Acute Arthritis

Lyme disease can be differentiated from other causes of acute arthritis on the basis of synovial fluid analysis.

Type of

Arthritis

Color Transparency Viscosity Volume

(in ml)

WBC count

(per mm3)

PMN

cellcount (%)

Gram stain Gram Culture polymerase chain reaction

(PCR) test

Crystals
Normal Clear Transparent High/thick < 3.5 < 200 < 25 Negative Negative Negative Negative
Lyme arthritis Yellow Cloudy Low Often >3.5 3,000 to 100,000

(mean: 25,000)

> 50 Negative Negative Positive (85 percent) Negative
Gonococcal arthritis Yellow Cloudy-opaque Low Often >3.5 34,000 to 68,000 > 75 Variable (< 50 percent) Positive (25 to 70 percent) Positive (> 75 percent) Negative
Non-gonococcal arthritis Yellowish-green Opaque Very low Often >3.5 > 50,000 (> 100,000 is

more specific)

> 75 Positive (60 to

80 percent)

Positive (> 90 percent) Negative
Inflammatory:

crystalline arthritis

(e.g.Gout, Pseudogout)

Yellow Cloudy Low/thin Often >3.5 2,000 to 100,000 > 50 Negative Negative Negative Positive
Inflammatory:

non-crystalline arthritis

(e.g. Rheumatoid arthritis, reactive arthritis)

Yellow Cloudy Low/thin Often >3.5 2,000 to 100,000 > 50 Negative Negative Negative Negative
Noninflammatory arthritis

(e.g. Osteoarthritis)

Straw Translucent High/thick Often >3.5 200 to 2,000 < 25 Negative Negative Negative Negative
Hemorrhagic Red Bloody Variable Usually >3.5 Variable 50-75 Negative Negative Negative Negative

Differentiating Lyme disease from other diseases

Lyme disease must be differentiated from other causes of rash and arthritis[18][19][20]

Disease Findings
Nongonococcal septic arthritis
  • Presents with an acute onset of joint swelling and pain (usually monoarticular)
  • Culture of joint fluid reveals organisms
Acute rheumatic fever
  • Presents with polyarthritis and rash (rare presentation) in young adults. Microbiologic or serologic evidence of a recent streptococcal infection confirm the diagnosis.
  • Poststreptococcal arthritis have a rapid response to salicylates or other antiinflammatory drugs.
Syphilis
  • Presents with acute secondary syphilis usually presents with generalized, pustular lesions at the palms and soles with generalized lymphadenopathy
  • Rapid plasma reagin (RPR), Venereal Disease Research Laboratory (VDRL) and Fluorescent treponemal antibody absorption (FTA-ABS) tests confirm the presence of the causative agent.
Reactive arthritis (Reiter syndrome)
  • Musculoskeletal manifestation include arthritis, tenosynovitis, dactylitis, and low back pain.
  • Extraarticular manifestation include conjunctivitis, urethritis, and genital and oral lesions.
  • Reactive arthritis is a clinical diagnosis based upon the pattern of findings and there is no definitive diagnostic test
Hepatitis B virus (HBV) infection
  • Presents with fever, chills, polyarthritis, tenosynovitis, and urticarial rash
  • Synovial fluid analysis usually shows noninflammatory fluid
  • Elevated serum aminotransaminases and evidence of acute HBV infection on serologic testing confirm the presence of the HBV.
Herpes simplex virus (HSV)
  • Genital and extragenital lesions can mimic the skin lesions that occur in disseminated gonococcal infection
  • Viral culture, polymerase chain reaction (PCR), and direct fluorescence antibody confirm the presence of the causative agent.
HIV infection
  • Present with generalized rash with mucus membrane involvement, fever, chills, and arthralgia. Joint effusions are uncommon
Gout and other crystal-induced arthritis
  • Presents with acute monoarthritis with fever and chills
  • Synovial fluid analysis confirm the diagnosis.
Lyme disease
  • Present with erythema chronicum migrans rash and monoarthritis as a later presentation.
  • Clinical characteristics of the rash and and serologic testing confirm the diagnosis.

References

  1. Lyme Disease Information for HealthCare Professionals. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/lyme/healthcare/index.html Accessed on December 30, 2015
  2. Relapsing Fever Information. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/relapsing-fever/ Accessed on December 30, 2015
  3. Rocky Mountain Spotted Fever Information. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/rmsf/ Accessed on December 30, 2015
  4. Disease index General Information (2015). http://www.cdc.gov/parasites/babesiosis/health_professionals/index.html Accessed on December 30, 2015
  5. Rocky Mountain Spotted Fever Information. Centers for Disease Control and Prevention (2015). \http://www.cdc.gov/tularemia/index.html Accessed on December 30, 2015
  6. General Disease Information (TBE). Centers for Disease Control and Prevention (2015). http://www.cdc.gov/vhf/tbe/ Accessed on December 30, 2015
  7. General Tick Deisease Information. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/coloradotickfever/index.html Accessed on December 30, 2015
  8. Babesiosis. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/parasites/babesiosis/disease.htmlAccessed December 8, 2015.
  9. Goldenberg DL, Cohen AS (1976) Acute infectious arthritis. A review of patients with nongonococcal joint infections (with emphasis on therapy and prognosis). Am J Med 60 (3):369-77. PMID: 769545
  10. 10.0 10.1 Le Dantec L, Maury F, Flipo RM, Laskri S, Cortet B, Duquesnoy B et al. (1996) Peripheral pyogenic arthritis. A study of one hundred seventy-nine cases. Rev Rhum Engl Ed 63 (2):103-10. PMID: 8689280
  11. Vassilopoulos D, Chalasani P, Jurado RL, Workowski K, Agudelo CA (1997) Musculoskeletal infections in patients with human immunodeficiency virus infection. Medicine (Baltimore) 76 (4):284-94. PMID: 9279334
  12. Morgan DS, Fisher D, Merianos A, Currie BJ (1996) An 18 year clinical review of septic arthritis from tropical Australia. Epidemiol Infect 117 (3):423-8. PMID: 8972665
  13. Schattner A, Vosti KL (1998) Bacterial arthritis due to beta-hemolytic streptococci of serogroups A, B, C, F, and G. Analysis of 23 cases and a review of the literature. Medicine (Baltimore) 77 (2):122-39. PMID: 9556703
  14. Deesomchok U, Tumrasvin T (1990) Clinical study of culture-proven cases of non-gonococcal arthritis. J Med Assoc Thai 73 (11):615-23. PMID: 2283490
  15. De Jonghe M, Glaesener G (1995) [Type B Haemophilus influenzae infections. Experience at the Pediatric Hospital of Luxembourg.] Bull Soc Sci Med Grand Duche Luxemb 132 (2):17-20. PMID: 7497542
  16. Luttrell LM, Kanj SS, Corey GR, Lins RE, Spinner RJ, Mallon WJ et al. (1994) Mycoplasma hominis septic arthritis: two case reports and review. Clin Infect Dis 19 (6):1067-70. PMID: 7888535
  17. “Lyme Disease Diseases With Similar Symptoms – Lyme Disease Health Information – NY Times Health”. Retrieved 2013-03-14.
  18. Rompalo AM, Hook EW, Roberts PL, Ramsey PG, Handsfield HH, Holmes KK (1987). “The acute arthritis-dermatitis syndrome. The changing importance of Neisseria gonorrhoeae and Neisseria meningitidis”. Arch Intern Med. 147 (2): 281–3. PMID 3101626.
  19. Rice PA (2005). “Gonococcal arthritis (disseminated gonococcal infection)”. Infect Dis Clin North Am. 19 (4): 853–61. doi:10.1016/j.idc.2005.07.003. PMID 16297736.
  20. Bleich AT, Sheffield JS, Wendel GD, Sigman A, Cunningham FG (2012). “Disseminated gonococcal infection in women”. Obstet Gynecol. 119 (3): 597–602. doi:10.1097/AOG.0b013e318244eda9. PMID 22353959.


Template:WikiDoc Sources

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2], Ilan Dock, B.S.

Overview

Because Lyme disease is a tick-borne disease, an individual is at a heightened risk of contracting it when traveling or residing within endemic regions. Risk within endemic regions is higher during the spring and summer months, with peaks in June and July. Other factors that may increase the risk of contracting Lyme disease include owning a domesticated animal such as a dog or cat, as both of these pets may be potential hosts for a blacklegged tick. In summary, individuals who spend much of their time outdoors and/or have pets that go outdoors and who live in endemic regions, are at a higher risk of contracting tick-borne diseases.

Risk factors

Individuals who spend time outdoors and/or have pets that go outdoors in endemic regions are at risk for tick-borne disease. [1]

Exposure to ticks

  • Individuals with frequent exposure to dogs and who reside near wooded areas or areas with high grass may also be at increased risk of tick-borne infection.
  • Individuals with outdoor occupations and who work outside with bare or exposed skin are at a high risk of contracting Lyme disease.
  • Failing to remove a tick as soon as you see it on your skin (the longer a tick is attached to your skin, the greater your risk of developing Lyme disease) also increases risk of developing Lyme disease.[2]

Endemic Regions

  • About 95% of all reported cases are confined to 14 states including Connecticut, Delaware, Maine, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia, and Wisconsin.[3][4]
  • Any individual traveling or living within these five geographic areas including New England, Mid-Atlantic, East-North Central, South Atlantic, and West North-Central is at a heightened risk of exposure to Lyme disease.

Seasonal Variation

  • The majority of Lyme disease cases are reported during the summer months of May to August.
  • Case incidence increases in May (estimated 20,000 cases reported between the years 2001-2015), peaks in June and July (estimated 70,000-80,000 cases reported between the years 2001-2015), and tapers off in August (just above 30,000 cases reported between the years 2001-2015).
Confirmed Lyme disease cases by month of disease onset–United States, 2001-2015 Source: CDC.gov

Rarer forms of Transmission

References

  1. General Information (2015). http://www.cdc.gov/ticks/index.html Accessed on December 30, 2015
  2. “Lyme disease: All – MayoClinic.com”. Retrieved 2013-03-14.
  3. “Lyme disease data tables | Lyme Disease | CDC”.
  4. “Data and Statistics | Lyme Disease | CDC”.
  5. Lyme disease transmission. Centers for Disease Control and Prevention. http://www.cdc.gov/lyme/transmission/index.html Accessed February 9, 2016.


Template:WikiDoc Sources

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Lyme disease may present as a red, expanding rash called erythema migrans (EM) along with flu-like symptoms such as fatigue, arthralgia, myalgias, headache, fever and/or chills, stiff neck, anorexia, and regional lymphadenopathy. EM resolves in approximately 28 days in untreated patients. Lyme disease is effectively managed by prompt treatment.

Untreated infection may spread from the site of the bite to other parts of the body, producing a range of symptoms including neurological, cardiac and dermatological manifestations. Many of these symptoms will resolve over a period of weeks to months, even without treatment. However, lack of treatment can result in additional complications. Lyme arthritis is the most frequently presented symptom in late disseminated Lyme disease.

Prognosis is mainly affected by a failure to treat in a timely manner as well as simultaneous infections with other tick-borne diseases. Sometimes, patients with Lyme disease have symptoms that last months to years after treatment with antibiotics. These symptoms includes muscle and joint pains, cognitive defects, sleep disturbance, or fatigue. The condition is referred to as post-treatment Lyme disease syndrome (PTLDS).

Natural History

Stage 1: Early Localized Lyme disease (3-30 Days Post-tick Bite)

  • Some people may get these flu-like symptoms in addition to an EM rash, but in some, these flu-like symptoms may be the only evidence of infection.
  • EM occurs in approximately 70-80% of infected persons and begins at the site of a tick bite after a delay of 3-30 days (average is about 7 days).
  • Early EM may be homogenously erythematous without any central clearing.
  • EM gradually expands over a period of several days, and can reach up to 12 inches (30 cm) across. Parts of the rash may clear as it enlarges, resulting in a bullseye appearance.

Stage 2: Early Disseminated Lyme disease (Days to Weeks Post-tick Bite)

  • Many of these symptoms will resolve over a period of weeks to months, even without treatment. However, lack of treatment can result in additional complications.

Stage 3: Late Disseminated Lyme disease (Months-to-Years Post-tick Bite)

Complications

Stage 3 or late disseminated Lyme disease can cause long-term joint inflammation (Lyme arthritis) and heart rhythm problems. Brain and nervous system problems are also possible, and may include:

Lingering Symptoms After Treatment (Post-treatment Lyme disease Syndrome)

Prognosis

References

  1. Wormser GP, Masters E, Nowakowski J, McKenna D, Holmgren D, Ma K; et al. (2005). “Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions”. Clin Infect Dis. 41 (7): 958–65. doi:10.1086/432935. PMID 16142659.
  2. Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ, Newman JH, Rahn DW; et al. (1983). “The early clinical manifestations of Lyme disease”. Ann Intern Med. 99 (1): 76–82. PMID 6859726.
  3. Wormser GP, McKenna D, Carlin J, Nadelman RB, Cavaliere LF, Holmgren D; et al. (2005). “Brief communication: hematogenous dissemination in early Lyme disease”. Ann Intern Med. 142 (9): 751–5. PMID 15867407.
  4. Wormser, Gary P. (2006). “Early Lyme Disease”. New England Journal of Medicine. 354 (26): 2794–2801. doi:10.1056/NEJMcp061181. ISSN 0028-4793.
  5. Steere AC, Schoen RT, Taylor E (1987). “The clinical evolution of Lyme arthritis”. Ann Intern Med. 107 (5): 725–31. PMID 3662285.
  6. Krause PJ, Foley DT, Burke GS, Christianson D, Closter L, Spielman A (2006). “Reinfection and relapse in early Lyme disease”. Am. J. Trop. Med. Hyg. 75 (6): 1090–4. PMID 17172372.
  7. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS; et al. (2006). “The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America”. Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130.
  8. Cairns V, Godwin J (2005). “Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms”. Int J Epidemiol. 34 (6): 1340–5. PMID 16040645.
  9. Klempner MS, Hu LT, Evans J; et al. (2001). “Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease”. N Engl J Med. 345 (2): 85–92. PMID 11450676.
  10. Kirsch M, Ruben FL, Steere AC, Duray PH, Norden CW, Winkelstein A (1988). “Fatal adult respiratory distress syndrome in a patient with Lyme disease”. JAMA. 259 (18): 2737–9. PMID 3357244.
  11. Oksi J, Kalimo H, Marttila RJ; et al. (1996). “Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature”. Brain. 119 (Pt 6): 2143–54. PMID 9010017.
  12. Waniek C, Prohovnik I, Kaufman MA, Dwork AJ (1995). “Rapidly progressive frontal-type dementia associated with Lyme disease”. J Neuropsychiatry Clin Neurosci. 7 (3): 345–7. PMID 7580195.
  13. Cary NR, Fox B, Wright DJ, Cutler SJ, Shapiro LM, Grace AA (1990). “Fatal Lyme carditis and endodermal heterotopia of the atrioventricular node”. Postgrad Med J. 66 (772): 134–6. PMID 2349186.
  14. “First Lyme Disease Death Told”. Los Angeles Times. 1990-09-26.


Template:WikiDoc Sources

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

There is insufficient evidence to recommend routine screening for Lyme disease.

Screening

There is insufficient evidence to recommend routine screening for Lyme disease.

References


Template:WikiDoc Sources

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings |ECG |X-ray |CT scan |MRI |Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Template:Spirochetal diseases


cs:Lymeská borelióza da:Borreliose de:Lyme-Borreliose el:Μπορρελίωση it:Malattia di Lyme nl:Lymeziekte sk:Lymská borelióza fi:Borrelioosi sv:Borrelia wa:Må d’ Lyme



Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH